compounded glp 1 california GLP-1 Treatment GLP-1 Compounding: When Innovation May

However, the UACR reduction was not significantly different (Tuttle et al., 2018)

A more complete plateau, when the scale essentially stops moving, typically arrives between 12 and 18 months for most patients, though a small proportion will continue losing weight for up to two years

These effects are mediated by: Improved endothelial function and nitric oxide bioavailability Reduced vascular inflammation and oxidative stress Stabilization of atherosclerotic plaque Enhanced cardiac metabolism and mitochondrial efficiency From a longevity standpoint, microdosing may maintain low-grade GLP-1 receptor activation within vascular tissue, supporting arterial flexibility, autonomic tone, and lipid regulation without the gastrointestinal intolerance often limiting high-dose use

Differences in study design, patient populations, and outcome measures make it difficult to draw firm conclusions